Brokerages Set Marker Therapeutics, Inc. (NASDAQ:MRKR) Target Price at $10.17

Marker Therapeutics, Inc. (NASDAQ:MRKR) has been assigned an average recommendation of “Buy” from the seven analysts that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have given a buy rating and three have issued a strong buy rating on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $10.1667.

MRKR has been the topic of several recent research reports. Zacks Research upgraded Marker Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, November 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Marker Therapeutics in a research report on Tuesday. UBS Group reissued a “buy” rating on shares of Marker Therapeutics in a research note on Monday, December 8th. HC Wainwright started coverage on shares of Marker Therapeutics in a research note on Monday, December 8th. They issued a “buy” rating and a $10.00 price objective for the company. Finally, Wall Street Zen cut shares of Marker Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, November 30th.

Marker Therapeutics Price Performance

MRKR stock opened at $1.28 on Monday. The firm has a 50 day simple moving average of $1.10 and a two-hundred day simple moving average of $1.22. The stock has a market cap of $21.34 million, a PE ratio of -1.04 and a beta of 1.35. Marker Therapeutics has a one year low of $0.81 and a one year high of $4.73.

Marker Therapeutics (NASDAQ:MRKR) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.57. The company had revenue of $1.23 million during the quarter, compared to the consensus estimate of $0.72 million. Marker Therapeutics had a negative net margin of 304.56% and a negative return on equity of 92.35%. On average, research analysts expect that Marker Therapeutics will post -0.65 EPS for the current fiscal year.

Hedge Funds Weigh In On Marker Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Two Sigma Investments LP bought a new stake in Marker Therapeutics in the third quarter valued at approximately $33,000. Virtu Financial LLC purchased a new position in shares of Marker Therapeutics in the third quarter worth $25,000. Finally, Jane Street Group LLC bought a new stake in Marker Therapeutics during the 2nd quarter valued at $33,000. 22.39% of the stock is currently owned by institutional investors.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.